Improved CD4 T-cell profile and inflammatory levels in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination.
I. Herrero-Fernandez, I. Rosado-Sanchez, M. Genebat, L. Tarancon-Diez, M. d. M. Rodriguez-Mendez, M. d. M. Pozo-Balado, M. d. C. Lozano, E. Ruiz-Mateos, M. Leal, Y. M. Pacheco
The paper examines how maraviroc-containing therapy affects CD4 T-cell profiles and inflammation in HIV patients, linking these factors to improved HBV vaccine response.
bioRxiv · Apr 10, 2018Immunology